NCT06253871
A Phase 1/2 Study of IAM1363 in HER2 Cancers
At risk: Primary completion moved at least 9 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 2027 to Oct 2028 Show 9 more changesShow less
- Phase changed: Phase 1 → Phase 1/2
- Eligibility criteria expanded, about 11 words
- Enrollment increased: 383 → 463 participants
- Interventions modified
- Trial arms changed: 1 → 4
- Secondary endpoints: details revised at 6 of 6 entries
- Site details revised at 6 of 53 sites
- Study title revised
- Study description shortened, about 4 words
- Minor Site contacts updated at 1 of 53 sitesv13
- Minor Trial sites expanded: 48 → 53 locationsv12
Notable Primary completion pushed from Mar 2027 to Dec 2027v11 Show 7 more changesShow less
- Primary endpoint(s) modified
- Enrollment increased: 243 → 383 participants
- Eligibility criteria expanded, about 39 words
- Trial sites expanded: 45 → 48 locations
- Study completion pushed from Mar 2028 to Dec 2028
- Secondary endpoints: 14 to 6
- Study description expanded, about 14 words
- Minor Study sites: 39 to 45v10
Show 7 earlier versionsHide 7 earlier versions
- Minor Study sites: 28 to 39v9
- Minor Study sites: 12 to 28v8
Notable Primary completion date: Apr 2028 to Mar 2027v7 Show 8 more changesShow less
- Primary endpoints: 4 to 7
- Eligibility criteria expanded, about 1 word
- Enrollment target: 287 to 243
- Study completion date: Apr 2028 to Mar 2028
- Interventions: IAM1363 (Drug), Trastuzumab (Drug) to IAM1363 (Drug)
- Secondary endpoints: 11 to 14
- Study description shortened, about 29 words
- Study arms: 2 to 1
- Minor Study sites: 9 to 12v6
- Minor Study sites: 4 to 9v5
- Minor Study sites: 1 to 4v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 2024 to Mar 25, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Oral treatment with IAM1363 capsules, administered in increasing dose levels starting at 120 mg QD in 21-day cycles.
Oral treatment with IAM1363 capsules, administered in 21-day cycles. Participants randomized to receive either 960 mg QD or 1200 mg QD.
Oral treatment with IAM1363 capsules or tablets, administered in up to 5 cohorts at 960 mg QD in 21-day cycles.
Oral treatment with IAM1363 capsules or tablets, administered in combination with either capecitabine + trastuzumab (HER2+ metastatic breast cancer), capecitabine + zanidatamab (HER2+ metastatic breast cancer), T-Dxd (HER2+ gastroesophageal adenocarcinoma), and pembrolizumab +/- carboplatin +/- pemetrexed (HER2 amplified or overexpressing non-squamous NSCLC) in 14 or 21-day cycles.
Drugs: IAM1363, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab, Oral treatment with IAM1363 capsules or tablets, administered in combination with T-Dxd, Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed
Sites
53 sites in 8 countries
United States 29, Spain 6, Italy 4, South Korea 4, France 3, Ireland 3, United Kingdom 3, Netherlands 1